Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration

Human Molecular Genetics

Volumn 23, Issue 17, 2014, Pages 4621-4638

  Tsika, Elpida ^a   Glauser, Liliane ^a   Moser, Roger ^a   Fiser, Aris ^a   Daniel, Guillaume ^a   Sheerin, Una Marie ^b   Lees, Andrew ^b   Troncoso, Juan C ^c   Lewis, Patrick A ^b,d   Bandopadhyay, Rina ^e   Schneider, Bernard L ^a   Moore, Darren J ^a,f  

^a EPFL   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF READING   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f VAN ANDEL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARKIN; SOMATOMEDIN B RECEPTOR; SORLA PROTEIN; SORTILIN; UNCLASSIFIED DRUG; VACUOLAR PROTEIN SORTING 35 HOMOLOG; VESICULAR TRANSPORT PROTEIN; VPS35 PROTEIN, HUMAN;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CELL CULTURE; BRAIN TISSUE; CELL STRESS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENDOSOME; FEMALE; FIBROBLAST; GAIN OF FUNCTION MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEWY BODY; LYSOSOME; MALE; MISSENSE MUTATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NULL ALLELE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STABILITY; RAT; RAT MODEL; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION; TISSUE LEVEL; VERY ELDERLY; VIRAL GENE DELIVERY SYSTEM; YEAST; ANIMAL; BRAIN; CELL CULTURE; CELL DEATH; DEPENDOPARVOVIRUS; GENETICS; HEK293 CELL LINE; METABOLISM; MIDDLE AGED; MOUSE; MUTATION; PATHOLOGY; PHYSIOLOGICAL STRESS; PROTEIN TRANSPORT; SACCHAROMYCES CEREVISIAE; SPRAGUE DAWLEY RAT; TRANSPORT VESICLE;

AGED; AGED, 80 AND OVER; ANIMALS; BRAIN; CELL DEATH; CELLS, CULTURED; DEPENDOVIRUS; DOPAMINERGIC NEURONS; FEMALE; HEK293 CELLS; HUMANS; MALE; MICE; MIDDLE AGED; MUTATION; NERVE DEGENERATION; PARKINSON DISEASE; PROTEIN STABILITY; PROTEIN TRANSPORT; RATS, SPRAGUE-DAWLEY; SACCHAROMYCES CEREVISIAE; STRESS, PHYSIOLOGICAL; TRANSPORT VESICLES; VESICULAR TRANSPORT PROTEINS;

EID: 84905646690     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu178     Document Type: Article

References (38)

1. Lang, A.E. and Lozano, A.M. (1998) Parkinson's disease-first of two parts. N. Engl. J. Med., 339, 1044-1053.
2. Lang, A.E. and Lozano, A.M. (1998) Parkinson's disease. Second of two parts. N. Engl. J. Med., 339, 1130-1143.
3. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
4. Gasser, T. (2009) Mendelian forms of Parkinson's disease. Biochim. Biophys. Acta, 1792, 587-596.
5. Moore, D.J., West, A.B., Dawson, V.L. and Dawson, T.M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci., 28, 57-87.
6. Vilarino-Guell, C., Wider, C., Ross, O.A., Dachsel, J.C., Kachergus, J.M., Lincoln, S.J., Soto-Ortolaza, A.I., Cobb, S.A., Wilhoite, G.J., Bacon, J.A. et al. (2011) VPS35 mutations in Parkinson disease. Amer. J. Hum. Genet., 89, 162-167.
7. Zimprich, A., Benet-Pages, A., Struhal, W., Graf, E., Eck, S.H., Offman, M.N., Haubenberger, D., Spielberger, S., Schulte, E.C., Lichtner, P. et al. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Amer. J. Hum. Genet., 89, 168-175.
8. Sharma, M., Ioannidis, J.P., Aasly, J.O., Annesi, G., Brice, A., Bertram, L., Bozi, M., Barcikowska, M., Crosiers, D., Clarke, C.E. et al. (2012) A multi-centre clinico-genetic analysis of theVPS35gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J. Med. Genet., 49, 721-726.
9. Deng, H., Gao, K. and Jankovic, J. (2013) The VPS35 gene and Parkinson's disease. Mov. Disord., 28, 569-575.
10. Seaman, M.N., McCaffery, J.M. and Emr, S.D. (1998) A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. J. Cell Biol., 142, 665-681.
11. Bonifacino, J.S. and Hurley, J.H. (2008) Retromer. Curr. Opin. Cell Biol., 20, 427-436.
12. Seaman, M.N. (2005) Recycle your receptors with retromer. Trends Cell Biol., 15, 68-75.
13. Hierro, A., Rojas, A.L., Rojas, R., Murthy, N., Effantin, G., Kajava, A.V., Steven,A.C.,Bonifacino, J.S. andHurley, J.H. (2007) Functional architecture of the retromer cargo-recognition complex. Nature, 449, 1063-1067.
14. Paravicini, G., Horazdovsky, B.F. and Emr, S.D. (1992) Alternative pathways for the sorting of soluble vacuolar proteins in yeast: a vps35 null mutant missorts and secretes only a subset of vacuolar hydrolases. Mol. Biol. Cell, 3, 415-427.
15. Waxman, E.A. and Giasson, B.I. (2009) Molecular mechanisms of alphasynuclein neurodegeneration. Biochim. Biophys. Acta, 1792, 616-624.
16. Dusonchet, J., Bensadoun, J.C., Schneider, B.L. and Aebischer, P. (2009) Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. Neurobiol. Dis., 35, 32-41.
17. Gieselmann, V., Hasilik, A. and von Figura, K. (1985) Processing of human cathepsin D in lysosomes in vitro. J. Biol. Chem., 260, 3215-3220.
18. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M.S., Shen, J., Takio, K. and Iwatsubo,T. (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol., 4, 160-164.
19. Lee, V.M., Goedert, M. and Trojanowski, J.Q. (2001) Neurodegenerative tauopathies. Annu. Rev. Neurosci., 24, 1121-1159.
20. Simon-Sanchez, J., Schulte, C., Bras, J.M., Sharma, M., Gibbs, J.R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S.W., Hernandez, D.G. et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet., 41, 1308-1312.
21. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A. et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet., 41, 1303-1307.
22. Coleman, M. (2005) Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci., 6, 889-898.
23. Lee, M.K., Stirling,W.,Xu,Y.,Xu,X.,Qui,D.,Mandir,A.S., Dawson, T.M., Copeland, N.G., Jenkins, N.A. and Price, D.L. (2002) Human alphasynuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A., 99, 8968-8973.
24. Lo Bianco, C., Ridet, J.L., Schneider, B.L., Deglon, N. and Aebischer, P. (2002) Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A., 99, 10813-10818.
25. Follett, J., Norwood, S.J., Hamilton, N.A., Mohan, M., Kovtun, O., Tay, S., Zhe, Y., Wood, S.A., Mellick, G.D., Silburn, P.A. et al. (2013) The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. Traffic, 15, 230-244.
26. Bi, F., Li, F., Huang, C. and Zhou, H. (2013) Pathogenic mutation in VPS35 impairs its protection against MPP(+) cytotoxicity. Int. J. Biol. Sci., 9, 149-155.
27. MacLeod, D.A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B.D., Marder, K.S., Honig, L.S., Clark, L.N., Small, S.A. et al. (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron, 77, 425-439.
28. Wen, L., Tang, F.L., Hong, Y., Luo, S.W., Wang, C.L., He, W., Shen, C., Jung, J.U., Xiong, F., Lee, D.H. et al. (2011) VPS35 haploinsufficiency increases Alzheimer's disease neuropathology. J. Cell Biol., 195, 765-779.
29. Scott, K.L., Kabbarah, O., Liang, M.C., Ivanova, E., Anagnostou, V., Wu, J., Dhakal, S., Wu, M., Chen, S., Feinberg, T. et al. (2009) GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature, 459, 1085-1090.
30. Deglon, N., Tseng, J.L., Bensadoun, J.C., Zurn, A.D., Arsenijevic, Y., Pereira de Almeida, L., Zufferey, R., Trono, D. and Aebischer, P. (2000) Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Therapy, 11, 179-190.
31. Alberti, S., Gitler, A.D. and Lindquist, S. (2007)Asuite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast, 24, 913-919.
32. Stafa, K., Trancikova, A., Webber, P.J., Glauser, L., West, A.B. and Moore, D.J. (2012) GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet., 8, e1002526.
33. Sheerin, U.M., Charlesworth, G., Bras, J., Guerreiro, R., Bhatia, K., Foltynie, T., Limousin, P., Silveira-Moriyama, L., Lees, A. and Wood, N. (2012) Screening for VPS35 mutations in Parkinson's disease. Neurobiol. Aging, 33, 838.e1-838.e5.
34. Ramonet, D., Podhajska, A., Stafa, K., Sonnay, S., Trancikova, A., Tsika, E., Pletnikova, O., Troncoso, J.C., Glauser, L. and Moore, D.J. (2012) PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum. Mol. Genet., 21, 1725-1743.
35. Trancikova, A., Mamais, A., Webber, P.J., Stafa, K., Tsika, E., Glauser, L., West, A.B., Bandopadhyay, R. and Moore, D.J. (2012) Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PloS One, 7, e47784.
36. Low, K., Aebischer, P. and Schneider, B.L. (2013) Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles. Hum. Gene Therapy, 24, 613-629.
37. Ramonet, D., Daher, J.P., Lin, B.M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L. et al. (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One, 6, e18568.
38. Daher, J.P., Pletnikova, O., Biskup, S.,Musso, A., Gellhaar, S., Galter, D., Troncoso, J.C., Lee, M.K., Dawson, T.M., Dawson, V.L. et al. (2012) Neurodegenerative phenotypes in an A53 T alpha-synuclein transgenic mouse model are independent of LRRK2. Hum. Mol. Genet., 21, 2420-2431.